Apogee Therapeutics (APGE) Net Cash Flow (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Net Cash Flow data on file, last reported at $320.2 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $320.2 million, up 1018.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $344.6 million (up 191.03% YoY), and the FY2025 annual result was -$10.5 million, down 144.88% from the prior year.
• Net Cash Flow improved to $320.2 million in Q1 2026 per APGE's latest filing, from $23.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $367.1 million in Q1 2024 and troughed at -$188.5 million in Q3 2024.
• A 5-year average of $46.0 million and a median of $4.8 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow soared 6036.13% in 2023, then sank 1122.77% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $149.3 million in 2022, then tumbled by 146.65% to -$69.7 million in 2023, then jumped by 133.03% to $23.0 million in 2024, then rose by 2.89% to $23.7 million in 2025, then jumped by 1252.74% to $320.2 million in 2026.
• Business Quant data shows APGE's Net Cash Flow at $320.2 million in Q1 2026, $23.7 million in Q4 2025, and -$16.6 million in Q3 2025.